Short-term management of XXXX with a new injectable form of @entity2847 .

@entity1 @entity2847 @entity227 @entity2013 @entity5 @entity4090 @entity6126 @entity10
Three cases (2 @entity1 , 1 @entity1 ) of expansive @entity2013 treated with a single 50-mg intramuscular dose of a new form of injectable, long-acting @entity2847 are presented. Clinical manifestations included @entity227 (2 cases), @entity10 (1 case), and @entity6126 (3 cases). Laboratory tests demonstrated high basal serum @entity4090 ( @entity4090 ) levels and evidence of involvement of other anterior pituitary hormones in all cases. Treatment was followed by marked improvement of symptoms paralleled by a sharp decrease of serum @entity4090 levels, which normalized in 1 case. Some other anterior pituitary functions also improved. Computed tomography scan revealed shrinkage of the @entity5 in all cases. There were no local or serious systemic side effects. These initial findings suggest that long-acting injectable @entity2847 has a place in the initial treatment of @entity2013 , especially for those with @entity227 . It can also be used to select @entity1 for surgery, in the cases where clinical and radiological improvement could not be obtained. The effects of long-term use remain to be established by further studies.
